Loading
A phase 1 trial of DNX-2401 run by M.D. Anderson Cancer Center, now recruiting.
MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma is a phase 1 interventional study registered as NCT03896568 by M.D. Anderson Cancer Center, with 36 participants planned, started 2019-02-12. Conditions recorded: IDH1 wt Allele, Recurrent Anaplastic Astrocytoma, Recurrent Glioblastoma, Recurrent Gliosarcoma and Recurrent Malignant Glioma. Interventions recorded: Oncolytic Adenovirus Ad5-DNX-2401 and Therapeutic Conventional Surgery.
Shares DNX-2401, DNAtrix, Brain and spinal cord tumours (all types), Glioma & glioblastoma and the tag pipeline.
Shares DNX-2401, DNAtrix, Glioma & glioblastoma, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares DNX-2401, DNAtrix, Brain and spinal cord tumours (all types) and the tag pipeline.
Shares DNX-2401, DNAtrix, Brain and spinal cord tumours (all types) and the tag pipeline.
Shares DNX-2401, DNAtrix, Glioma & glioblastoma and the tag pipeline.
Shares DNX-2401, DNAtrix, Brain and spinal cord tumours (all types) and the tag pipeline.
Shares DNX-2401, DNAtrix, Brain and spinal cord tumours (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/